The primary aim of neuromonitoring in patients with traumatic brain injury is early detection of secondary brain insults so that timely interventions can be instituted to prevent or treat secondary brain injury. Intracranial pressure monitoring has been a stalwart in neuromonitoring and is still very much the main parameter to guide therapy in brain injured patients in many centres. Cerebral oxygenation is also established as an important parameter for monitoring: global cerebral oxygenation is reliably measured using jugular venous oxygen saturation while brain tissue oxygen tension measurement allows focal brain oxygenation to be monitored. Near-infrared spectroscopy allows a non-invasive option for monitoring of regional cerebral oxygenation. Cerebral microdialysis makes focal measurements of markers of cellular metabolism and cellular injury and death possible, and it is in transition from being a research tool to being an important clinical tool in neuromonitoring. Multimodal monitoring allows different parameters of brain physiology and function to be monitored and can improve identification and prediction of secondary cerebral insults. Multimodal monitoring can potentially improve outcomes in patients with traumatic brain injury by promoting customised treatment strategies for individual patients in place of the commonplace practice of strict adherence to achieving the same standard physiological targets for every patient.
INTroduCTIoN
There is little doubt that traumatic brain injury (TBI) is a major cause of mortality and disability throughout the world, especially among young people. It is well known that TBI sets off a series of events that can lead to secondary brain injury 1 . These secondary insults consist of ischaemic, ionic, neurochemical and immunological processes, and can result in further damage to the injured brain 2 . Causes of these secondary insults can be intracranial, such as intracranial hypertension, cerebral oedema, disturbances of regional cerebral blood flow, seizures, excitotoxicity, mitochondrial dysfunction and metabolic disturbances, or systemic, such as hypoxaemia, hypotension, glucose and metabolic derangements, and anaemia 2, 3 . The prevention and minimisation of such secondary injury to the brain has thus become the main therapeutic target of modern TBI management 4 .
Neuromonitoring has become an essential tool for the intensive care physician for the timely identification and prevention of secondary cerebral insults 2 . The primary objectives of neuromonitoring in TBI are to detect ongoing secondary brain injury, to guide therapy as well as to predict outcome 5 . It is believed that if secondary insults can be recognised early, they can be better managed and outcome for patients can be improved. The Current Guidelines for the Management of Severe Head Injury stress the use of intracranial pressure (ICP) monitoring for the management of severe TBI patients 6 . However, there has not been any randomised clinical trial to support its routine use. In contrast, multimodality monitoring has been advocated by some 2,7-9 , although there is also no robust evidence to support that the use of such a monitoring method does improve the outcome of patients with severe TBI. Multimodality Review Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 monitoring refers to the monitoring of several parameters of brain physiology and function, and comprises several invasive and non-invasive techniques, including monitoring of intracranial pressure, brain oxygenation, brain metabolism and neurochemistry, cerebral blood flow, and brain electrical activity and function 8 . The vast array of information provided by multimodality monitoring may seem unwieldy to the uninitiated but to the experienced clinician, it is certainly advantageous to the management of severe TBI. Should one modality fail, one can always rely on the other modalities to provide information on brain physiology 5 . This review is focused on the modalities of ICP monitoring, brain tissue oxygenation monitoring and neurochemical monitoring of severe TBI in the Neurologic Intensive Care.
INTrACrANIAl pressure (ICp)
Despite the multitude of advances in neuromonitoring in recent years, ICP is still the most commonly monitored parameter in the neurosurgical intensive care unit. This is because the monitoring of ICP and its derived parameter, cerebral perfusion pressure (CPP), are important components of the management protocols for TBI in most units. There exists a vast quantity of clinical evidence to support the use of ICP monitoring in guiding therapeutic interventions and assessing prognosis, although there is a lack of Class 1 evidence to show the its benefit on outcome after severe TBI 10, 11 . Outcome prediction is improved with the addition of ICP monitoring 12 , and it is established that a poor prognosis accompanies sustained elevation of ICP 13, 14 . A study of ICP of data from the Traumatic Coma Data Bank demonstrated that beyond the usual outcome predictors in age, admission motor score and abnormal pupillary responses, the proportion of time that ICP was above 20mmHg was highly significant in outcome prediction 15 . The current guidelines by Brain Trauma Foundation (BTF) recommend ICP monitoring in all patients with severe head injury and either an abnormal computed tomographic (CT) head scan or a normal CT scan with at least 2 of the following risk factors: age >40 years; systolic blood pressure <90mmHg; unilateral or bilateral motor posturing 6 . ICP monitoring allows the physician to institute therapeutic interventions to prevent or reduce ICP increases, and allows the physician to monitor the effectiveness of the therapy. The normal ICP is 7 to 15 mmHg in a supine adult. Therapy is indicated when ICP is >20mmHg in an adult with TBI 16 .
However, 45 to 80% of patients with TBI develop intracranial hypertension with ICP >20mmHg despite treatment 12, 15 . Vik et al investigated the use of cumulative "dose" of intracranial hypertension by measuring the area under curve of ICP versus time in TBI patients and found a significant relationship between ICP "dose" and mortality rate, outcome and 6 months, and the worst Marshall CT classification 17, 18 .
The placement of a ventriculostomy catheter with the tip in a lateral ventricle, and the catheter connected to a standard pressure transducer, is considered the "gold standard" for ICP measurement. It measures global ICP, allows drainage of cerebrospinal fluid (CSF) to treat intracranial hypertension, allows in vivo calibration, and allows administration of drugs such as antibiotics 2,19. However, this is the most invasive of ICP monitoring methods and insertion of the ventricular catheter may be difficult if there is displacement of the ventricle due to severe cerebral swelling or the presence of an intracranial mass lesion. The rate of ventriculostomy-related infection is up to 11% 20 . This method also does not allow simultaneous drainage of CSF and monitoring of ICP 19 . As an alternative to ventricular catheters, probes with microtransducer tips can be placed in the brain parenchyma or the subdural space either through a skull bolt or via an open procedure. Various technologies are available: fibre-optic catheters where a change of ICP causes a change in the reflection of a light beam; catheter with a miniature strain gauge pressure sensor at the tip where a change of ICP causes a change in electrical resistance 11, 19 ; and catheter using pneumatic technology where any pressure change is sensed by a small air pouch balloon at the end of the catheter 11 . The advantages of microtransducer systems include ease of use, reliability 21 , and low infection and procedure-related complication rates 22 . A major drawback is that there exists a small zero drift of the sensor with time, although in vitro testing revealed a minor drift of 0.6 ± 0.9 mmHg after 5 days of use 11, 19 . The system also does not allow in vivo calibration. Another important disadvantage is that the probe measures only the local pressure, which may not reflect the true ICP as intracranial pressure gradients can exist in TBI 23 . This begs the question of the ideal position of the probe. In diffuse brain injury, there should not be any differences in the hemispheric ICPs. If there is a significant focal lesion, ICP should be monitored on the same side as the lesion, or bilaterally if Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 possible 24 . Subarachnoid and epidural monitoring devices are available, but they are rarely used now due to limited accuracy of the devices 25 . Lumbar CSF pressures are no longer monitored due to the lack of reliability of the ICP estimate and due to the inherent dangers in the presence of increased ICP 11, 19 . Non-invasive methods of ICP monitoring have also been developed. Sonographic measurement of the optic nerve sheath, sonographic monitoring of cranial diameter pulsations, measurement of tympanic membrane displacement by impedance audiometry, and CT (computer tomography) scan classification of ICP are explored but none of these have been conclusively useful in the clinical setting as yet 26 . Table 1 summarises the various commonly used modalities for ICP monitoring.
The measurement of ICP provides a number of additional clinical information such as the analysis of ICP waveforms and the calculation of secondary indices (CPP, pressure reactivity index and pressure volume compensatory reserve) 27 . CPP is the difference between mean arterial blood pressure (MAP) and ICP. It is easily performed, is easily monitored continuously, and it is the most widely used surrogate for cerebral blood flow (CBF) estimation. As a result, CPP is used as a therapeutic target in many units. The BTF includes CPP in its management guidelines 28 . There is much controversy surrounding the decision on the optimal CPP threshold. Rosner et al stressed an aggressive approach to CPP management, even advocating a CPP of 80mmHg or more 29 . On the other hand, the Lund approach advocates a lower CPP: as low as 50mmHg as long as ICP is normal 27 . The current BTF Guidelines recommend a CPP threshold of 60mmHg 28 . The purpose of maintaining CPP at a certain threshold is to improve CBF at at-risk cerebral regions. However, CBF can improve with an increase in CPP only if autoregulation is impaired or if CPP is below the lower limit of autoregulation 30 . Autoregulation curve can be shifted to the right after brain injury; it is also frequently disrupted or even completely abolished in TBI 27, 31 . Cerebral autoregulation may also be preserved in TBI patients, and this is advantageous as ICP can be reduced with the autoregulation-mediated compensatory vasoconstriction response. Using perfusion CT imaging, Wintermark et al showed that in some patients, CBF was in the ischaemic range in spite of a high CPP, and also that the extent of disruption of autoregulatory function cannot be elucidated just from baseline measurements of CPP and CBF 32 . Thus, the state of cerebral autoregulation becomes a heterogeneous spectrum of adaptive changes in the cerebrovascular resistance in response to changes in the perfusion pressure throughout all regions of the brain 27 . Moreover, inappropriately high CPP can result in complications such as acute respiratory distress syndrome 33 and poorer outcomes 19 . Different regions of the brain have different susceptibilities to ischaemic stress due to that fact that the state of autoregulation and CBF requirements differ between normal and injured brain tissue. Because of this, it is difficult to pinpoint the optimal threshold of CPP for management of TBI patients, and this threshold may vary from patient to patient, and may vary over time. Hence, an individualised approach to CPP management may be prudent 27 . Thus far, there have not been any randomised clinical trials involving ICP monitoring and ICP-or CPP-directed therapy; the question whether these improve outcome is still unanswered. Irrespective of this fact, a meta-analysis by Stein et al, reviewing trials and case series reported after 1970 comparing the patients with and without ICP monitoring and intensive treatment, showed that there was a significantly lower mortality rate (12%) in the group with intensive therapy and a higher rate (6%) of favourable outcome, and this was independent of temporal effects on treatment 34 .
The pressure reactivity index (PRx) is a measure that reflects the state of pressure autoregulation of the cerebral vasculature. This index can be derived from calculating a moving correlation coefficient between spontaneous slow wave fluctuations in ICP and MAP 35 , with the value of the index between -1 and 1. A negative PRx indicates a cerebral vasculature with intact pressure autoregulation whereas a positive PRx indicates a defective autoregulatory vasomotor system. An abnormal PRx is associated with a poor prognosis in TBI 19, 36 . A high mortality rate of >50% was found with a PRx of >0.3535. PRx is also found to correlate well with transcranial Doppler ultrasound assessment of cerebrovascular autoregulation 36 . Zweifel suggested using PRx as a global measure of cerebrovascular reserve for vasomotor reactivity 36 . PRx can be continuously monitored at the bedside 19, 27 . It has been suggested that the monitoring of PRx can be used to derive individualised CPP thresholds [35] [36] [37] , and this should allow for optimal CBF.
BrAIN oxygeNATIoN
Maintaining an optimal level of cerebral oxygenation has long been recognised as an important component of the strategy in the management of TBI 8, 9, 38 . There is evidence that ischaemia accounts for much of cellular damage in brain injury 8 . Ischaemia can occur at early and late stages of brain injury. Furthermore, cerebral ischaemia can be induced with excessive hyperventilation 39 , highlighting the importance of monitoring for ischaemia and making appropriate therapeutic modifications, e.g. adjustment of mechanical ventilation, to prevent or minimise secondary brain injury in the intensive care setting. CPP has conventionally been used as a marker for CBF in monitoring for cerebral ischaemia. However, as mentioned earlier in this article, the use of CPP is highly controversial, attracting much criticism 8 . In addition, monitoring CBF alone may not be enough as there is much heterogeneity in cerebrovascular responses and metabolic demands in both injured and uninjured regions of the brain; areas with high metabolic demand may be ischaemic even with normal CBF, while low CBF may suffice for areas with decreased metabolic demand 9 . Pathologic changes in ICP and CPP are not always responsible for secondary insults to the brain 40 . Despite the best efforts to resuscitate using well-established ICP/CPP protocols, cerebral hypoxia is not consistently prevented 40 and there has not been a palpable improvement in clinical outcome, albeit a decrease in mortality 41 .
Modalities that are currently available for monitoring cerebral oxygenation include jugular venous saturation (SjvO 2 ) monitoring (assesses global brain oxygenation invasively), brain tissue oxygen tension (PbtO 2 ) monitoring (assesses focal brain oxygenation invasively), and near infrared spectroscopy (NIRS) monitoring (assesses regional brain oxygenation noninvasively). Table 2 summarises a comparison of these modalities.
Jugular Venous oxygen saturation Monitoring
The use of SjvO 2 monitoring as an indirect measurement of cerebral oxygenation has been in place since the 1980s 42, 43 . Its clinical role in the assessment of global cerebral ischaemic and hyperaemic states as well its value in prognostication for TBI has been well-established 8 . This technique involves the retrograde insertion of a catheter into the internal jugular vein (IJV) via a central approach.
The catheter tip is positioned in the jugular bulb, and this is confirmed by the tip being seen at the level of the mastoid process (or at the lower border C1 vertebra) on a lateral neck X-ray 42 . The IJV with dominant drainage is usually catheterised as the monitored SjvO 2 will then accurately reflect the global brain oxygenation 44 (the compressed IJV causing the larger ICP increase is the dominant one), CT identification of the larger jugular foramen, or by sonographic comparison of the sizes of both IJVs 2,42 . If it is not able to be determined, the right IJV is usually presumed to be the dominant side 45 . It has been shown that the difference between the SjvO 2 measured from both IJVs can be >10% in a large proportion of patients 46, 47 . SjvO 2 can be measured by using a co-oximetry on a blood sample drawn from the jugular bulb, or it can be continuously determined by fibreoptic oximetry 2 . The normal range for SjvO 2 is 55 to 75%. Ischaemic cerebral blood flow is considered to occur when SjvO 2 is low, and this can be due to hypoxaemia, inadequate CBF from various causes (e.g. excessive hyperventilation, reduced CPP and vasospasm), or increased cerebral metabolism (CMRO 2 ) 48 . In TBI, a SjvO 2 of <50% is associated with a poor prognosis 2, 48 . However, the lower physiologic limit has been challenged by some, and a lower ischaemic threshold of 45% has been suggested 49, 50 .
On the other hand, a high SjvO 2 is luxuriant flow and this can be a result of hyperaemia, decreased cerebral metabolic demand (such as due to cell death or mitochondrial dysfunction), increased systemic oxygen delivery, or microvascular shunting from impaired oxygen extraction or diffusion in injured brain tissue 48 . After TBI, CMRO 2 is believed to be decreased; the degree of decrease in CMRO 2 has strong implications for outcome 8 .
Hyperaemia is believed to be attributed to a defective cerebral autoregulatory system and is predictive of a poor outcome 8 . A high SjvO 2 from decreased cerebral metabolism is a stronger predictor of a poor outcome when compared to hyperaemia 48 . Indeed, with its ability to monitor the balance between oxygen delivery and utilisation in real time, SjvO 2 monitoring provides a range of clinical applications: it allows detection of cerebral ischaemia, guides hyperventilation therapy, and allows optimisation of CPP and fluid management 42 . The harm of cerebral hypoperfusion from excessive hyperventilation cannot be stressed enough, and guidance from SjvO 2 monitoring can help achieve "optimal hyperventilation" in the management of TBI. SjvO 2 monitoring does have significant limitations. SjvO 2 is a global measure of cerebral oxygenation; it has a low sensitivity but high specificity in detecting ischaemia 42 . It is rather insensitive to the detection of focal areas of ischaemia, and it has a poor correlation with measurements of PbtO 2 in areas with focal lesions in TBI 51 . Coles et al used positron emission tomography (PET) to demonstrate that SjvO 2 <50% was only achieved after 13 ± 5% of brain tissue volume became ischaemic 51 . This relative insensitivity to regional ischaemia has contributed to the controversy of the site of SjvO 2 monitoring. In cases with focal lesions, some will recommend monitoring the ipsilateral side as about 70% of cerebral venous blood drain into the ipsilateral IJV; in cases with diffuse lesions, the dominant IJV is cannulated 47 . On the other hand, some advocate cannulating the dominant IJV in all cases 42 . Another limitation is the presence of extracerebral contamination of the jugular bulb blood sample; blood from the scalp, skull and meninges accounts for 3% of jugular bulb blood 42 .
Erroneous readings due to migration of the tip of the catheter are also a common problem, and frequent calibration is needed 42 . A few SjvO 2 -derived indices have been evaluated. Arterio-jugular difference of oxygen content (AJDO 2 ) is the ratio of CMRO 2 to CBF and has been used as a global measure of cerebral oxygenation. Stocchetti et al showed that a low AJDO 2 was associated with a poor outcome while normal or high AJDO 2 was indicative of a better prognosis 53 . Cerebral lactate level is believed to correlate with degree of brain injury and prognosis.
Poca et al showed that arteriojugular differences of lactate did not correlate with cerebral tissue lactate levels and could not be relied on to rule out cerebral ischaemia 54 . Despite the relatively long history the use of SjvO 2 monitoring, there has been no evidence that it impacts on patient outcome.
Brain Tissue oxygenation Monitoring
Maintenance of adequate cerebral oxygenation is the main goal in the management of TBI. PbtO 2 monitoring has proven to be an increasingly important component in the armamentarium of monitors used in neurocritical care. There have been many studies investigating the role of PbtO 2 monitoring in TBI and strategies for PbtO 2 -directed therapy have been developed 48 in brain tissue 8 . It is also reasonable to consider it as a reflection of the balance of the factors that influence the perfusion and diffusion of oxygen through brain tissue 48 . These factors include arterial partial pressure of oxygen, arterial partial pressure of carbon dioxide, haemoglobin level, ICP, CPP, CBF, and tissue barriers to diffusion 40, 48 .
Pathologic processes, such as perivascular oedema, cytotoxic cell swelling, arteriovenous shunting and microvascular collapse, can impair the diffusion of oxygen through brain tissue and thus affect PbtO 2 levels 57 . It has been shown that PbtO 2 correlates with the product of CBF and arteriovenous difference in oxygen tension, thus a low PbtO 2 value may be more indicative of impaired oxygen diffusion instead of reduced oxygen supply or metabolism 58 . The normal PbtO 2 is thought to be in the range of 25 to 30 mmHg 40, 48 . Prognosis worsens as PbtO 2 progressively decreases below 20mmHg 59 . The critical threshold of 10mmHg is considered to be "hypoxic" and is strongly associated with neuronal injury and poor outcome 8 56 reported that there were significant reductions in mortality rate in TBI patients who underwent PbtO 2directed treatment in comparison with those who underwent conventional ICP/CCP-directed treatment. Spiotta et al also found that outcome was worse for patients who responded poorly to treatment to improve PbtO 2 . However, in these 3 studies, the mortality rates for patients who received ICP/CCP-directed therapy were higher than expected from mortality rates reported in some clinical studies on TBI 56 . A mortality rate of 36% was reported from analysis of data on severe TBI extracted from the Traumatic Coma Data Bank 41 . On the other hand, Martini et al 66 found that the mortality rate for patients who had PbtO 2 -directed therapy was higher, and that PbtO 2 monitoring might be associated with worse neurological outcome. However, a major limitation of the study was that the baseline prognostic characteristics of the 2 groups of patients were markedly different. Besides optimising CBF, CPP, ICP and haemoglobin concentrations, increasing oxygen delivery to injured brain tissue by increasing fraction of inspired oxygen (FiO 2 ) and PaO 2 has been investigated. There is some evidence that PbtO 2 increases with increased inspired oxygen, and this is associated with improvement in neurochemical markers of metabolism 8 . However, a recent review found that studies using PET to investigate the influence of hyperoxia on cerebral oxygenation did not find an improvement in oxygen utilisation by the brain 67 . Hlatky et al found that the increase in PbtO 2 by hyperoxia therapy was small in brain regions where the CBF was <20ml/100g/min when compared to the regions where the CBF was >20ml/100g/min, and concluded that the regions of the brain that would most likely benefit from increased oxygen delivery were the least likely to have improved PbtO 2 68 . A recent randomised clinical trial showed that increasing the dissolved cerebral oxygen concentration by using hyperbaric oxygen therapy could achieve an improvement in oxidative cerebral metabolism and reduction in ICP, but a PbtO 2 of ≥20 mmHg was required for a significant effect 69 .
PbtO 2 monitoring is safe and has low rates of infection and post-insertion hematoma formation 40 . The main limitation of PbtO 2 is that it measures only focal brain oxygenation, and it does not necessarily reflect global brain oxygenation. Because of marked spatial heterogeneity in the injured brain, the position of the microprobe is crucial. In diffuse brain injury, the probe can be sited in the right frontal white matter; in focal injury, the probe may be placed in the area of interest such the penumbra or the pericontusional region 5, 40 . Another limitation is that PbtO 2 is influenced by many factors as elucidated earlier. Besides ischaemic factors, pathologic changes affecting diffusion of oxygen through brain tissue as well as PaO 2 do influence PbtO 2 . As such, interpretation of any change in PbtO 2 readings can be challenging to the clinician. Although it has been established that low PbtO 2 is associated with poor outcomes, further research is needed to investigate whether PbtO 2 -directed therapy benefits patients.
Near-infrared spectroscopy (NIrs)
NIRS is a non-invasive technique that can be used to continuously monitor cerebral oxygenation over multiple regions of the brain. This technique is based on the transmission and absorption of near-infrared electromagnetic radiation (700 to 1,000 nm) at various wavelengths as it passes through tissue, and the principle behind this is that near-infrared radiation penetrates tissue well and its attenuation is influenced by many factors 2, 48, 70 . As oxy-and deoxyhaemoglobin have different absorption spectra, cerebral oxygenation can be estimated from their relative absorption of near-infrared radiation. Factors that can affect the absorption include skull thickness, myelin sheath, cerebrospinal fluid, ambient light and changes in extracranial blood flow 48 . The development of analysis of NIRS signals has seen progress from simple continuous wave analysis to time-resolved analysis (time or frequency domain) to spatially resolved techniques 48 . Early monitors allow only trend monitoring of changes in concentrations of tissue chromophores, but technical advances in spatially resolved spectroscopy have enabled absolute measurements of cerebral tissue oxygen saturation (ScO 2 ), which is a composite of oxygen saturation of arterial, venous and capillary components of the tissue in the field of view of the monitor 70 . ScO 2 reflects the balance between cerebral oxygen supply and utilisation. Attempts have been made to define normal values for ScO 2 and the thresholds at which hypoxia/ischaemia occurs. Some have concluded that it is difficult to ascertain precise reference ranges and thresholds for hypoxia/ischaemia 70 . One contributing factor is that there is marked variability in the baseline values of ScO 2 . The normal range of ScO 2 is thought to be between 60 to 75% 48, 70 , with a variation in baseline values of up to 10% 71 , and hypoxic/ ischaemic thresholds are likely to be individual and disease-specific. Definition of thresholds is also made harder by the lack of standardisation of the commercially available NIRS monitors, the different algorithms and measured variables used by the various devices, and the resulting limitations of comparing the various devices and their corresponding studies 70 . The tissue oxygen index (TOI: ratio of oxygenated to total tissue haemoglobin) was used in patients who underwent carotid endarterectomy in an attempt to define a threshold for ischaemia. Cerebral ischaemia after carotid clamping was detected by the use of electroencephalography (EEG), and it was suggested that a decrease of 13% from the baseline TOI signalled a threshold for cerebral ischaemia 72 . Kurth et al 73 showed that at a hypoxic ScO 2 level of 35% for more than 2 hours in a piglet model, the incidence of permanent neurological damage progressively increased at a rate of 15% every hour, and this was heralded by abnormalities in NIRS variables during reperfusion. ScO 2 level of 35% lasting for less than 2 hours was not associated with any significant neurological deficit. These findings suggest that a viability-time threshold for hypoxic brain injury using ScO 2 can be defined; that NIRS can be used to prognosticate; and that there exists a window period of a few hours following the onset of ischaemia/hypoxia for intervention to prevent or minimise neurological injury. It is also possible to measure changes in the concentrations of cytochrome c oxidase (CCO), which is the terminal complex of the electron transfer chain in mitochondria 2, 70 . This has been validated in animal studies as an assessment of cellular energy status. Thus, CCO brings forth a potential for evaluation of intramitochondrial redox state as well as sufficiency of cerebral oxygen supply and utilisation in TBI 2,70 . Newer NIRS devices have been adapted to measure CCO continuously, and CCO measurements using NIRS has been used to show increased oxidation state of cerebral mitochondria after normobaric hyperoxia 70, 74 . One major limitation of NIRS is that its signal can be significantly affected by extracerebral factors. NIRS can be rendered less accurate in TBI, due to factors such as haematoma collections, cerebral swelling, subdural air collection and a wet chamber between the skin and the optode 48 . These problems have been considerably addressed with Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 the use of spatially resolved spectroscopy, which has been demonstrated to have high sensitivity and specificity to intracranial oxygenation changes 75 , and it has been evaluated against SjvO 2 and PbtO 2 measurements in response to normabaric hyperoxia in patients with TBI 76 . Indeed, CCO measurements by NIRS tend to be less susceptible to extracerebral contamination as the concentration of mitochondria in the brain is higher than other tissue in the human body 70 . Currently available NIRS systems involve the placement of optodes on the forehead, allowing assessment of regional cerebral oxygenation, and this limits the detection of cerebral oxygenation in sites distant to the optodes. Now, multiprobe NIRS devices allow simultaneous monitoring of multiple regions, hence giving a more global assessment of cerebral oxygen sufficiency 48, 70 . As of now, amid conflicting reports on the efficacy of NIRS 48 , there has not been any randomised clinical trial to ascertain the clinical efficacy of NIRS in TBI, and there has not been any study to evaluate NIRSdirected therapy on outcome in TBI.
BrAIN NeuroCheMIsTry
Cerebral microdialysis was first introduced for laboratory use in the 1960s before gaining popularity for clinical monitoring of neurochemistry in the intensive care unit in the 1990s [77] [78] [79] [80] . The principles of cerebral microdialysis have been succinctly described in another review 79 . Monitoring cerebral tissue biochemistry offers the opportunity for timely detection of impending or early onset secondary brain injury, hence permitting judicious application of neuroprotective techniques. The cascade of pathological processes set off in secondary brain injury leads to changes in cerebral metabolism and brain cell damage. This can be reflected as a change in the biochemical milieu in cerebral tissue 79 . Just as with PbtO 2 monitoring catheters, the importance of microdialysis catheter location has been highlighted. It has been demonstrated that microdialysis analyte measurements from the penumbra zone of focal traumatic lesions and those from normal brain tissue ipsilateral and contralateral to the side of the traumatic lesion differ significantly 81 . Thus, by placing the microdialysis catheter in the at-risk penumbra zone of focal traumatic lesions, neurochemical changes due to secondary insults in the region of the brain most susceptible to injury can be measured 79 . A second probe can be placed in normal brain tissue if needed 80 . It is recommended that the catheter be placed in the right frontal lobe in the case of diffuse injury 80 . The most commonly measured microdialysis analytes include glucose, lactate, pyruvate, glutamate and glycerol 2, 79, 80 . Information on bioenergetic sufficiency or the lack of it is provided by measurements of glucose, lactate, pyruvate and glutamate 80 . Microdialysis glutamate levels also reflect the excitatory amino acid activity in the injured brain 80 . Glycerol is released after enzymatic degradation of cell membrane phospholipids during failure of cellular metabolism, and hence is a marker of cell damage 2, 80 . A summary of the characteristics of microdialysis is presented in Table 2 .
Glucose is the main substrate for cellular metabolism in the brain. After TBI, microdialysis glucose levels typically decrease, and a concentration blow 0.66mmol/L in the first 50 post-TBI hours is related to a worse prognosis 82 . However, the correlation between ischaemia and low microdialysis glucose levels is poor 82, 83 , intimating the likelihood that low microdialysis glucose levels may be related to hyperglycolysis rather than ischaemia 79 . The relative concentrations of microdialysis lactate and pyruvate reflect the extent of cerebral anaerobic metabolism. The microdialysis lactate-pyruvate ratio (LPR) is considered a more dependable and robust indicator of cerebral tissue ischaemia when compared to lactate alone 79 . Thus, the LPR is the most widely used microdialysis indicator of ischaemia and is typically markedly increased in severe brain tissue ischaemia/hypoxia, with an elevated LPR greater than the threshold of 20 to 25 associated with a worse prognosis 2, 79 . LPR has been correlated with regional oxygen extraction fraction measured with PET 84 . Although LPR has been conventionally used as a marker of ischaemia, it is found that it is not as specific for ischaemia as previously thought; there is evidence that markedly raised LPR is found in the absence of ischaemia and this may be the result of failure of mitochondria to utilise delivered oxygen 83, 85 . Increased LPR has been classified: Type 1 reflects the conventional ischaemic metabolic state, in which microdialysis lactate is increased while pyruvate is decreased; the nonischaemic raised LPR is designated as Type 2, in which a decreased microdialysis pyruvate is the prime feature 78 . The Type 2 anomaly may be a result of a failure in the glycolysis process or an inadequacy of glucose as a substrate due to shunting of glucose to other pathways like the pentose phosphate pathway 80, 86 showed that persistent metabolic crisis, as indicated by increased LPR, was predictive of the extent of frontal lobe atrophy at six months, and that the percentage of time of elevated LPR correlated with the extent of frontal lobe atrophy, but not with global cerebral atrophy. Thus, microdialysis LPR has the potential to be a clinically useful but nonspecific indicator of metabolic distress in brain tissue.
It has been demonstrated that hyperglycaemia is associated with a poorer outcome in critically ill patients, and hence there has been interest in rigorous glycaemic control using insulin in patients with severe TBI. Vespa et al 88 compared the effects of intensive insulin therapy and a more relaxed insulin regime and found that there was a significantly greater decrease in microdialysis glucose levels in the intensive insulin therapy group (70% vs 15%). The intensive group was also associated with a higher microdialysis glutamate level and an increased microdialysis lactate/pyruvate ratio, but there was no difference in mortality in both treatment groups. Oddo et al 89 There was a significantly greater prevalence of low microdialysis glucose (65% vs 36%) and brain energy crisis (defined as microdialysis glucose <0.7mmol/L and lactate/pyruvate ratio >40; 25% vs 17%) in the tight glycaemic control group. Brain energy crisis was independently predicted by systemic glucose level and insulin dose, after adjusting for ICP and CPP. Non-survivors had lower microdialysis glucose concentrations compared to survivors, and there was a higher mortality rate associated with brain energy crisis.
Glutamate is the major excitatory amino acid in cerebral tissue 90 . Excessive release in TBI may cause excitotoxicity, which is a form of secondary neurotoxic insult to the brain. Injury can occur as a result of excessive calcium and sodium influx through glutamate-mediated ion channels 79, 90 , mitochondrial dysfunction, and dendritic morphological changes culminating in cell death by delayed apoptosis or rapid necrosis 90 . Increased extracellular glutamate in the brain has been observed after cerebral ischaemia and TBI 80, 90 and has been correlated with high ICP91 and poor prognosis 79, 91 . A moderate increase in microdialysis glutamate may signify reversible ischaemia; markedly elevated glutamate levels associated with an increased microdialysis glycerol can be a sign of irreversible neuronal damage 5 . Chamoun et al 90 found that there was a tendency for a higher mortality rate with a high initial microdialysis glutamate in the first 24 hours post-injury: 30% mortality rate in patients with microdialysis glutamate level >20µmol/L compared with 18% with level <20 \ µmol/L. Two patterns of changes in glutamate levels over time were described: in Pattern 1, glutamate levels tended to normalise over time, while glutamate levels tended to rise over time or remain abnormally high in Pattern 2. It was demonstrated that Pattern 1 was associated with a lower mortality rate (17.1% vs 39.6%) and a more favourable functional outcome (41.2% vs 20.7%). Microdialysis glutamate is considered a late marker of cellular distress 80 and its clinical role in monitoring in TBI is still being investigated.
Glycerol is released into cerebral extracellular fluid space after degradation of cell membrane phospholipids during cerebral metabolic distress [78] [79] [80] . Thus, it has the potential to be a clinically important marker of cerebral ischaemia/hypoxia. At present, there is a surfeit of evidence to validate its specificity for ischaemia/hypoxia 78 . Glycerol from systemic sources as well as conversion from glucose may potentially contribute to the extracellular glycerol concentration 78 . Clausen et al investigated the relationships between cerebral extracellular glycerol, PbtO 2 , CPP and outcome in a large cohort of 76 patients with severe TBI 92 . It was found that the mean microdialysis glycerol concentration was typically raised during the first 24 hours post-injury, apparently the result of the primary injury, before an exponential decrease over the subsequent 3 days. Despite the finding that CPP <70mmHg and PbtO 2 <10mmHg correlated with increased mean microdialysis glycerol, individual episodes below the same thresholds without a concomitant increase in microdialysis glycerol were often observed. Moreover, there was no significant difference in the mean microdialysis glycerol concentrations between patients with favourable and unfavourable outcomes.
Another study failed to demonstrate any association between microdialysis levels and secondary clinical events like elevated ICP and decreased CPP 93 . These results suggest that more work is needed to validate the clinical value of microdialysis glycerol. Other microdialysis analytes have also Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 been investigated: cytokines 80, 94 , nitric oxide metabolites 80, 95 , N-acetylaspartate 80 and amyloid proteins 96 . At present, evidence for their clinical use is lacking.
Post-traumatic seizures have been recognised to occur frequently in TBI patients 97 . It is not until recent years that a high frequency of nonconvulsive seizures and non-convulsive status epilepticus is detected with the use of continuous electroencephalography 80, 98 , and an increased mortality rate is associated with prolonged status epilepticus 98 . Post-traumatic seizures have been associated with increased levels of microdialysis glutamate 99 . It has also been demonstrated that non-convulsive seizures detected with electroencephalography is associated with increased ICP and raised microdialysis LPR, suggesting that seizures can result in or worsen intracranial hypertension, and can potentiate cerebral metabolic distress, which can result in permanent cellular injury, hence making post-traumatic seizures an important target for treatment 98 . Cortical spreading depolarisation (CSD) was previously thought to be benign but is now found to be a common and potentially pathogenic phenomenon in TBI 80 . Using rapid sequence microdialysis, Hashemi et al 100 showed that there was significant decrease in glucose concentration and increase in lactate concentration during the hyperaemic phase of CSD, and the degree of depression of glucose was proportional to the number of depolarisations. The authors suggested that a vicious cycle can be set off, in which CSDs triggering glucose depletion and metabolic distress may lead to more CSDs, until terminal depolarisation ensues.
Microdialysis has been used to investigate the effects of hypothermia in critically ill patients. In a study on TBI patients, changes in brain neurochemistry suggested that mild hypothermia provided neuroprotection: microdialysis LPR, lactateglucose ratio (LGR) and glycerol concentrations in perilesional tissue and LPR in "normal" cerebral tissue decreased with hypothermia. In comparison, the LPR, LGR and glycerol levels in perilesional tissue were higher than those in "normal" tissue during normothermia 80 .
As discussed in an earlier part of this review, there is interest in normobaric hyperoxia therapy in TBI. Tisdall et al 74 demonstrated that with FiO 2 of 100%, there were an increase in PbtO 2 of 7.2kPa, a decrease in microdialysis lactate concentration of 0.26mmol/L, a decrease in microdialysis LPR of 1.6 and an increase in oxidised cytochrome c oxidase concentration of 0.21µmol/L. No significant changes in ICP or arterial or microdialysis glucose were found. The authors concluded that the findings were consistent with increased aerobic metabolism and that normobaric hyperoxia can potentially improve clinical outcome in TBI. On the other hand, Nortje et al 101 compare the effects of hyperoxia (FiO 2 increases between 0.35 and 0.5) and normoxia on microdialysis parameters, PbtO 2 and oxygen-15 PET and found that hyperoxia significantly increased mean PbtO 2 from 28 ± 21 mmHg to 57 ± 47 mmHg while there were no changes in microdialysis lactate and pyruvate levels. There was a statistically significant decrease in microdialysis LPR in the hyperoxia group (32.5 ± 9.0 vs 34.1 ± 9.5) but the authors doubted the clinical significance of the result. In view of the potentially deleterious clinical effects of hyperoxia, hyperoxia therapy is not recommended as a form of standard treatment for TBI at present 67 .
Although tentative normal values for the most commonly monitored microdialysis analytes (glucose, lactate, pyruvate, glutamate and glycerol) has been described 79, 102103 , one must understand that values for these analytes do vary significantly over time post-injury within the individual patient, and there are wide inter-individual variations in these values too 77, 79 . As interpretation of an analyte measurement in isolation may prove to be difficult, microdialysis is probably best used for trend monitoring, and interpretation should be made in context with other modes of monitoring. There has been much research into how the use of cerebral microdialysis can impact on clinical decisionmaking. As discussed above, microdialysis may be useful as a prognostic indicator. Microdialysis may also be useful in directing hyperventilation therapy 104 , guiding management of CPP 105 as well as influencing the decision for decompressive craniectomy 79 . There has been an ever-expanding amount of information provided by the use of cerebral microdialysis in TBI, and there is accumulating evidence advocating its routine use in the clinical setting. However, there is an absence of level one evidence demonstrating its clinical value at present, and more prospective trials are needed to address this. Nonetheless, Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 cerebral microdialysis has the potential to be an integral part of the routine multimodal monitoring armamentarium in the management of TBI.
CoNClusIoN
The purpose of neuromonitoring in TBI is the early detection of pathological insults which can lead to secondary brain injury and subsequent permanent brain cell death, ultimately resulting in a poor clinical outcome. A mode of monitoring is only useful if it allows timely detection and identification of an insult, if it can influence a management decision, and/or if can provide a reasonably accurate prognosticating function. The principles of neuromonitoring are based on the assumption that there is an unequivocal link between secondary cerebral injury and a worse clinical outcome. In addition, the clinical significance of the monitored clinical event with reference to outcome has not been firmly established. Whether an intervention appropriate for an abnormal event exists, and if so whether the intervention will influence outcome remain pertinent questions. Monitoring on its own does not improve outcome if it does not lead to effective therapeutic management. At present, there is a lack of level one evidence for each mode of neuromonitoring. Despite this, multimodal monitoring does provide the clinician with wide array of useful information which can potentially assist in clinical decisionmaking. The challenge is the integration and analysis of this array of information which allows the generation of a reasonable and appropriate management plan. The clinician should develop the techniques of assimilation of vast amount of data, and not be intimidated by the inundation of information. Multimodal monitoring is probably best utilised as a tool to better understand the pathophysiological processes occurring in the individual TBI patient, and hence allow the clinician to form a customised management strategy for the individual patient rather than depend on a rigorous therapeutic regime aimed at achieving standard physiological targets. Coupled with future technological advances and development of software that assists the clinician in integration and interpretation of monitored parameters, this approach likely holds the promise of improving clinical outcomes of TBI patients.
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